Gentian is very pleased that we again can present our products and meet many of you face-to-face at conferences and exhibitions around the world. We have attended the successful AACC Annual Scientific Meeting & Clinical Lab Expo in Atlanta in end of September, and now we are really looking forward to exhibit at the IFCC EuroMedLab Conference in Munich end of November.
In the US, the NKF-ASN Task Force has been reassessing the inclusion of race in diagnosing kidney diseases. One key advantage of measuring cystatin C in addition to creatinine stems from the fact that cystatin C is less susceptible to factors that affect muscle mass (age, diet, sex, physical activity, race etc.), and in the final report the Task Force recommends "increased use of cystatin C combined with serum creatinine, as a confirmatory assessment of GFR or kidney function”. If you want to learn more about Gentian’s turbidimetric cystatin C assay please reach out to email@example.com.
Gentian is developing a turbidimetric SARS-CoV-2 Total Antibody Immunoassay in collaboration with the University in Tromsø (UiT). The quantitative antibody test captures the full immune response detecting antibodies targeting the S1 subunit with high sensitivity and specificity. It will be calibrated against the international WHO standard. Since the assay is platform agnostic, it can be seamlessly integrated in daily laboratory routine without additional infrastructure or workflow cost.
NKF-ASN Task Force: Recommends increased use of cystatin C
Based on input collected over 10 months from hundreds of patients, patient advocates, medical students, clinicians and scientists, the task force published its final report on September 23, 2021, recommending the "increased use of cystatin C combined with serum creatinine, as a confirmatory assessment of GFR or kidney function."
See you at EuroMedLab 2021
The 24th IFCC-EFLM European Conference for Clinical Chemistry and Laboratory Medicine EuroMedLab 2021 is to be held in Munich, Germany from November 28th to December 2nd 2021.
Gentian is looking forward to exhibit at EuroMedLab this year. We welcome you to come by our booth #201 or book a meeting in advance to learn more about our products and how we work to innovate diagnostic efficiency. You can book a meeting through firstname.lastname@example.org.
Sepsis Awareness Month: Calprotectin as an early marker to prevent sepsis
Early detection and intervention are critical to prevent the development of sepsis and severe events, as it is the most common cause of death in critically ill patients.
Gentian SARS-CoV-2 Total Antibody Assay for pandemic management
The development of our turbidimetric SARS-CoV-2 total antibody assay is in the final stage. The assay will provide a quantitative detection of the total antibody response targeting the S1 subunit of the spike protein. By targeting the S1 subunit we will cover both vaccination and natural infections, and provide a tool for the long-term surveillance of both the immunity of the society and also the virus behaviour including virus variations. If you have any additional questions about the assay don't hesitate to contact us on email@example.com.
Gentian's 20 years celebration
When Gentian was founded on 16th of August 2001 by the Sundrehagen brothers, Bård and Erling, we were not able to foresee our future growth. Thanks to the dedication and strong commitment by our employees over the years, Gentian has established itself as a leader in Particle-Enhanced Turbidimetric Immunoassay (PETIA) development. Today Gentian is an international company with a staff of over 50 employees.